Breaking Finance News

Venn Life Sciences Holdings PLC (LON:VENN) has been retained to Speculative Buy in a statement by Beaufort Securities today.

Beaufort Securities has retained Venn Life Sciences Holdings PLC (LON:VENN) to Speculative Buy in a report released on Thursday September 29, 2016.

Yesterday Venn Life Sciences Holdings PLC (LON:VENN) traded -3.96% lower at 25.00GBX. Venn Life Sciences Holdings PLC’s 50-day average is 28.19GBX and its two hundred day average is 26.18GBX. With the last close down -7.37% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 51,750 shares of the stock were exchanged, down from an average trading volume of 70,956

See Chart Below

Venn Life Sciences Holdings PLC (LON:VENN)

With a total market value of 0 GBX, Venn Life Sciences Holdings PLC has with a one year low of 17.55GBX and a one year high of 30.30GBX .

More About Venn Life Sciences Holdings PLC (LON:VENN)

Venn Life Sciences Holdings plc is a clinical research organization (CRO), which is engaged in providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organizations. The Company has the innovation segment, which is focused on developing and commercializing skin technologies. It provides drug development services through its subsidiary, Kinesis Pharma B.V. The Company's drug development services include clinical development, pharmaceutical development, non-clinical/pre-clinical development, drug candidate selection and drug development project management. The Company offers international clinical research services, including protocol development; feasibility and site selection; investigator and site selection; project management; site management and monitoring; vendor management, and quality assurance. The Company has its presence in the United Kingdom, Ireland, France, Netherlands, Germany and Singapore.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.